Drug Profile
Tapotoclax - Amgen
Alternative Names: AMG-176Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Amgen
- Developer AbbVie; Amgen; BeiGene; Genentech
- Class Amides; Antineoplastics; Cyclobutanes; Cyclohexenes; Ethers; Naphthalenes; Oxazepines; Small molecules; Spiro compounds; Sulfonamides
- Mechanism of Action MCL1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Preclinical Acute myeloid leukaemia
- No development reported Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in Australia (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in Canada (IV, Infusion)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in Germany (IV, Infusion)